Italy: Brief Analysis Of The Proposed Changes To The Medical Device Directive 93/42/EEC

Last Updated: 23 April 2004
Article by Paola Sangiovanni

I. Medical Devices In Europe.

The EU Commission well understands the strategic importance of the medical device sector for Europe. Europe is the second-largest world market for medical devices, and about 8,000 types of devices are on the Community market. Additionally, the medical device sector, a highly innovative industry, is recognized as having a crucial impact on the quality of life of European patients, and impacts health care and health policy.

II. Legal Framework.

The basic legal framework on medical devices was laid out at the Community level during the 1990s. Three main directives have been enacted, in the following three fields:

  • Directive 90/385/EEC on active implantable medical devices;
  • Directive 93/42/EEC on medical devices ("MDD"); and
  • Directive 98/79/EC on in-vitro diagnostic.

Other Directives in this area include Directive 2000/70/EC, on medical devices incorporating stable derivates of human blood or human plasma, and Directive 2003/32/EC, on medical devices manufactured utilizing tissues of animal origin.

This article focuses on the MDD and on the changes that the Commission is considering adopting to improve the regulation of the medical device sector.

III. The Medical Device Directive.

The MDD is based on the principles of the so-called "New Approach" to technical harmonization and standards. In accordance with the New Approach, the MDD does not analytically specify the technical features that medical devices must possess, but instead defines the essential requirements that devices must meet in order to be marketed. This approach appeared more appropriate for the regulation of rapidly evolving technologies, whereas a detailed specification of the devices’ features would have necessitated a constant update of the applicable provisions to describe the ever-changing state of the art.

Under the MDD, devices are subdivided into four categories, depending on the potential risks that are associated with their use. Assessment procedures for Class I devices are based on the manufacturer’s evaluation only, while Class IIa, IIb and III devices may be marketed only after a specific, so-called "Notified Body" has inspected them.

IV. CE Marking.

Manufacturers of medical devices must perform a risk/benefit analysis regarding any device, reduce risks to the minimum, adopt any adequate safety measure, and fully inform users of any remaining risk. Compliance with this required conformity assessment results in the issue of the CE mark, without which marketing of the device is not allowed. Only devices intended for clinical investigations and custom-made devices can be placed on the market without any CE marking.

The CE mark serves the purpose of certifying compliance with the MDD and allows the device to freely circulate within the Community market. Under the "safeguard clause," however, Member States are entitled to take appropriate interim measures to prohibit or restrict the circulation of certain devices on the market when they may compromise the health or safety of patients or other users. As measures taken under the safeguard clause represent an exception to the free circulation of devices on the European Market, they are reviewed by the Commission, which assesses whether they are justified in a particular case.

V. Proposed Changes to the Medical Device Directive.

Pursuant to Section 11(4) of the MDD, the Commission conducted a review of the regulatory framework and released a Communication to the Council and the European Parliament on Medical Devices, which was published on July 2, 2003 ("Communication").

While the present overall functioning of the regulatory framework appears to be appropriate, the Communication highlights a number of areas where improvement is possible.

A. Conformity Assessment. The Commission identified shortcomings in the conformity assessment, particularly in relation to the role of Notified Bodies, and suggests reinforcing the obligations to provide clinical data to Notified Bodies, their evaluation of the manufacturer’s quality system and of the data presented, as well as the provisions requiring market surveillance. Further, reclassification mechanisms for devices should be used more effectively. Lastly, designation and monitoring of Notified Bodies should be improved and the creation of a Notified Bodies Operations Group is suggested.

B. Transparency and Trust. There is a lack of transparent and easily accessible data on medical devices with respect to certifications by the Notified Bodies, and the European Database for Medical Devices (EUDAMED) has not been satisfactorily implemented. The Communication suggests the creation of "EU Notified Body public assessment reports" including selected information on devices, that would take due account of the legitimate interests of manufacturers. Further, communication must be improved between Member States and Notified Bodies, as well as among the Notified Bodies themselves. Information should be provided on a regular basis to the Health and Policy Forum, representing consumers, patients and healthcare professionals, and EUDAMED should be fully implemented.

C. Market Surveillance. The Commission expressed concern over the varied levels of market surveillance, and cooperation by Member States on this matter is highly encouraged. Also suggested are mechanisms to ensure early-warning exchanges between authorities, as well as communication to all Member States of measures restricting circulation on the market of medical devicesre.

D. Cooperation between Commission and Member States. The existing cooperation between the Commission and Member States has proved to be insufficient in politically sensitive areas, in the case of safeguard clauses, and in standardization. The Commission proposes the establishment of a high-level group on medical devices composed of EU Member States, candidate countries and EFTA, which would not jeopardize any other body active in this field (such as the Medical Device Expert Group).

E. Enlargement. The Commission hopes that implementation of the MDD in accession countries will be carried out with sufficient human resources, and recommends that such countries join the various working groups and participate in workshops, consultations and mentoring.

F. The International Dimension. Many Mutual Recognition Agreements (MRAs) covering medical devices have been signed, but only the ones with Switzerland and Australia are operational. The entering into force of MRAs should in any event be based on the existence of strict guarantees. The Global Harmonization Task Force (GHTF) is an informal group of representatives from national medical device regulatory bodies in Europe, Asia Pacific and North America that has gained more and more importance, and Europe should continue to play a leading role in the activities of GHTF.

The Communication further identifies a number of areas for regulatory modification, the main aim of which is defining new rules for conformity assessment and classification (e.g., elimination of certain classification anomalies, validity of conformity assessment certificates and retention of product files, clarifications on clinical evaluations), and at aligning the rules set in the Active Implantable Medical Devices Directive with the MDD.

Other measures recommended by the Communication include:

    1. The launch of a study on the medical device sector;
    2. The creation of a High Level Group allowing consultation between the Commission and national authorities;
    3. Regular provision of information to the Health Policy Forum;
    4. The creation of a pilot project on EUDOMED; and
    5. That MDEG monitor the current practices in the areas of vigilance and standardization.

VI. Reactions and Conclusions.

The Communication generally has been well received by the industry. UEAPME (Union Europeenne de l’Artisanat et des Petites et Moyennes Enterprises) pointed out the importance of extending the reach of the MDD to third countries and of including custom-made medical devices in such efforts. In conclusion, it can be said that the Commission is not overlooking the importance of the medical device sector and is seriously taking measures to improve the safety of devices, as well as to ensure strict vigilance on the enforcement of the MDD’s rules and regulations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions